Anti-CD19 CAR T as a feasible therapy for refractory/relapsed mixed phenotype acute leukemia patients

Pediatr Blood Cancer. 2022 Oct;69(10):e29657. doi: 10.1002/pbc.29657. Epub 2022 Apr 4.

Authors

Xiangqun Li¹, Kylan Chen², Hailong Zhang¹, Xian Zhang^{3

4}, Junfang Yang^{3

4}, Jing Liu¹, Jianwei Zheng¹, Fei Dong¹, Yongbo Zhu¹, Jiao Yu¹, Haihong Zhang¹, Peihua Lu^{3

4}, Bo Chen¹

Affiliations

¹ Kecellitics Biotech Company Ltd, Beijing, China.
² College of Natural Sciences, University of Texas, Austin, Texas, USA.
³ Lu Daopei Hospital, Langfang, Hebei, China.
⁴ Lu Daopei Institute of Hematology, Beijing, China.

PMID: 35373883
DOI: 10.1002/pbc.29657

No abstract available

Publication types

Letter

MeSH terms

Antigens, CD19
Humans
Immunotherapy, Adoptive
Leukemia*
Phenotype
Receptors, Chimeric Antigen*
Recurrence

Substances

Antigens, CD19
Receptors, Chimeric Antigen

Associated data

ChiCTR/ChiCTR2000038532